RECRUITING

Phase I Study of ICP-332 in Healthy Subjects

Talk to us

Conditions

Healthy Subjects

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

A multiple ascending dose phase I study of ICP-332 in healthy subjects

Official Title

A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-332 in Healthy Subjects

Quick Facts

Study Start:2024-07-23
Study Completion:2024-12-25
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06530966

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 55 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Voluntarily sign the informed consent form
  2. 2. Body mass index (BMI) of ≥ 18.5 kg/m2 and \< 30 kg/m2
  3. 3. Male or infertile female subjects who are between 18-55 years old (inclusive)
  1. 1. Significant current or past acute or chronic disease or condition.
  2. 2. A history of tuberculosis or current active/latent infection.
  3. 3. With a history of drug or food allergy, or allergy to any of the composition components of the study drug, or allergic disease.
  4. 4. Subjects with clinically significant abnormalities in the screening examinations.

Contacts and Locations

Study Contact

Alexia Lu
CONTACT
010-66609745
CO_HGRAC@innocarepharma.com

Study Locations (Sites)

Pharmaron CPC Inc.
Baltimore, Maryland, 21201
United States

Collaborators and Investigators

Sponsor: InnoCare Pharma Inc.

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-07-23
Study Completion Date2024-12-25

Study Record Updates

Study Start Date2024-07-23
Study Completion Date2024-12-25

Terms related to this study

Additional Relevant MeSH Terms

  • Healthy Subjects